60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
0.8537
-0.0203 (-2.32%)
At close: Dec 12, 2025, 4:00 PM EST
0.8600
+0.0063 (0.74%)
After-hours: Dec 12, 2025, 6:19 PM EST
SXTP Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$454,982
Profits / Employee
-$2,825,188
Market Cap
3.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SXTP News
- 3 days ago - 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 - GlobeNewsWire
- 23 days ago - 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire